Today: 13 November 2025
Subscribe
Browse Tag

pharmaceutical news

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc. (NASDAQ: MGRX), the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official access to their blockbuster GLP‑1 weight‑loss medications Zepbound and Wegovy. GlobeNewswire+1 What Mangoceuticals announced today In a press release and accompanying SEC Form 8‑K filed Thursday, Mangoceuticals said it has launched two integrated programs — MangoRx Direct and PeachesRx Direct — built around official access to GLP‑1 obesity drugs from Eli Lilly and Novo Nordisk. GlobeNewswire+2SEC+2 Under the new model:
13 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Meta description (160 chars): Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026. Date: November 11, 2025 Key takeaways India: Wegovy gets markedly cheaper — and it’s about more than price Novo Nordisk cut Wegovy’s Indian list prices across the dose range, with the monthly 2.4 mg pack now at ₹16,400 (down from ₹24,389 at launch) and the 0.25 mg starter at ₹10,850 (from ₹16,260). The company confirmed the reductions amid a fast‑evolving obesity market in the country. Reuters updated its initial “up
11 November 2025
 ·  ·  ·  ·  ·  · 
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK plc (NYSE: GSK; LSE: GSK) generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month high intraday. BioSpace+2 1) New research collaboration targets TB AN2 Therapeutics announced a collaboration with GSK to advance boron‑based leucyl‑tRNA synthetase (LeuRS) inhibitors for tuberculosis. The effort is supported by a third year of Gates Foundation funding and builds on prior work between AN2 scientists and GSK’s Global Health R&D team, according to the release. Thomas Breuer, GSK’s Chief Global
11 November 2025
 ·  ·  ·  · 
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company (NYSE: LLY) opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2 Today’s headlines at a glance Why the MeiraGTx move matters The MeiraGTx alliance hands Lilly a potential first‑in‑class therapy for LCA4 that, in a small study, has shown the ability to restore visual function in children born legally blind (regulators are evaluating expedited
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

Cidara Trading on Oct 3, 2025 On Friday morning Oct 3, CDTX was trading around $104 per share, up roughly 5.7% from Thursday’s close finviz.com. Trading volumes are high as investors digest the Oct 2 BARDA award news. (Finviz shows a sharp jump on Oct 2: GlobeNewswire’s BARDA release coincides with a ~5.7% stock bump finviz.com.) Cidara’s one-year chart is steeply upward – from around $10 a year ago to over $100 now (a nearly 900% one-year increase finviz.com). Most of that gain occurred since June, after positive Phase 2b results for CD388 and the $402M financing. CEO Jeffrey Stein noted on the Phase 3 dosing press release
3 October 2025
 ·  ·  ·  ·  ·  · 
Go toTop